- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 12.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.06. | NeOnc Technologies files to sell 10.02M shares of common stock by selling shareholders | 1 | Seeking Alpha | ||
| 09.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 06.06. | NeOnc Technologies appoints new chief clinical officer | 1 | Investing.com | ||
| 06.06. | NeOnc Technologies ernennt neuen Chief Clinical Officer | 2 | Investing.com Deutsch | ||
| 06.06. | NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs | 1 | GlobeNewswire (USA) | ||
| 03.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | NEONC TECHNOLOGIES HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 15.04. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets | 1 | GlobeNewswire (USA) | ||
| 14.04. | NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September | 182 | GlobeNewswire (Europe) | -- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 10.04. | NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President | 1 | GlobeNewswire (USA) | ||
| 08.04. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy | 100 | GlobeNewswire (Europe) | CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous... ► Artikel lesen | |
| 31.03. | NeOnc Falls Despite FDA Nod | - | Baystreet.ca | ||
| 31.03. | NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas | 2 | GlobeNewswire (USA) | ||
| 27.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments | 116 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic... ► Artikel lesen | |
| 26.03. | Biotech NeOnc Technologies' share registration declared effective ahead of Nasdaq direct listing | 2 | Renaissance Capital | ||
| 25.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.03. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market | 124 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. ("NeOnc" or the "Company," to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Evotec Aktie mit Verkaufssignal: Konter oder Sturz auf 5 Euro? | Die Evotec Aktie hat am Donnerstag ein charttechnisches Verkaufssignal ausgelöst. Mit einem XETRA-Schlusskurs von 6,568 Euro fiel der Kurs um mehr als vier Prozent und unterschritt dabei mehrere relevante... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | CARGO Therapeutics, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
NEONC TECHNOLOGIES HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -12,84 % bei einem Aktienkurs von 3,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.